Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema

27Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: To evaluate the effectiveness of intravitreal bevacizumab injection as primary treatment of diabetic macular oedema. Material and methods: Thirty eyes of 30 diabetic patients were treated with 2.5 mg of intravitreal bevacizumab injection as the primary therapy for diabetic macular oedema. The main outcome measures included best-corrected visual acuity, fundus fluorescein angiography, and macular oedema map values of Heidelberg retinal tomograph II (HRT II) before and after intravitreal injection. Results: The visual acuity increased in 24 of 30 eyes (80%) during a mean follow-up time of 5.6 months. The mean baseline best-corrected LogMAR value for visual acuities of the patients before intravitreal bevacizumab injection was 1.09Plusmn;0.23. After treatment, it was 0.90Plusmn;0.17 at the 1-month, 0.81Plusmn;0.24, at 3-month, and 0.77Plusmn;0.26 at the last visit examinations and the differences were significant when compared with baseline values (for each, P<0.001). The mean oedema map values significantly decreased by 33.3% at the last visit examination when compared with preinjection values (P<0.001). Mild anterior chamber inflammation was observed in four eyes (13.3%), which resolved in a week with topical corticosteroid. No other injection- or drug-related complications were observed. Conclusion: Intravitreal bevacizumab application provides significant improvement in visual acuity of diabetic patients and clinical course of macular oedema, and may therefore be a promising approach in the primary treatment of diabetic macular oedema. © 2009 Macmillan Publishers Limited All rights reserved.

References Powered by Scopus

Intravitreal triamcinolone for refractory diabetic macular edema

938Citations
N/AReaders
Get full text

Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies

733Citations
N/AReaders
Get full text

Treatment Techniques and Clinical Guidelines for Photocoagulation of Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study Report Number 2

0
712Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections

126Citations
N/AReaders
Get full text

Bevacizumab (Avastin) for the Treatment of Ocular Disease

119Citations
N/AReaders
Get full text

Diabetic retinopathy - An update

73Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Özkiriş, A. (2009). Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema. Eye, 23(3), 616–618. https://doi.org/10.1038/eye.2008.40

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

64%

Researcher 6

27%

Professor / Associate Prof. 1

5%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 21

81%

Nursing and Health Professions 2

8%

Agricultural and Biological Sciences 2

8%

Computer Science 1

4%

Save time finding and organizing research with Mendeley

Sign up for free